Why Cardiologists Kept an Eye on Vitamin D

People with low vitamin D levels die from cardiovascular disease at higher rates than those with sufficient levels. That pattern has held up across dozens of cohort studies and more than two decades of epidemiological work. The obvious question is whether that relationship is causal or simply a marker of poor health more broadly. In the last several years, large randomized controlled trials have finally given us data that can start to answer that question, and the picture is more complicated than either enthusiasts or skeptics predicted.

The Observational Case: Strong but Incomplete

A 2017 meta-analysis in Nutrients pooled data from 34 prospective studies and found that the lowest vitamin D tertile carried a roughly 52% higher risk of cardiovascular mortality compared with the highest tertile. The association persisted after adjusting for body mass index, physical activity, and smoking.

Several plausible mechanisms explain why this connection might be causal. Vitamin D receptors are expressed in cardiomyocytes, vascular smooth muscle, and endothelial cells. Animal and in-vitro work shows that vitamin D suppresses the renin-angiotensin-aldosterone system (RAAS), reduces vascular inflammation, and inhibits arterial calcification. Observational evidence from the Framingham Heart Study found that participants with 25(OH)D below 15 ng/mL (37 nmol/L) had more than double the risk of a cardiovascular event over five years compared with those above 15 ng/mL. That is a large signal, even accounting for confounders.

The problem with observational data alone is reverse causation and residual confounding. People who are ill, sedentary, or obese tend to have low vitamin D partly because they go outdoors less and partly because body fat sequesters the fat-soluble vitamin. Correcting for those factors statistically is never perfect.

VITAL: The Largest Randomized Trial on Vitamin D and Cardiovascular Events

The VITAL trial (Vitamin D and Omega-3 Trial) enrolled 25,871 U.S. adults aged 50 and older (women) and 55 and older (men) with no prior cardiovascular disease or cancer at baseline. Participants received either 2,000 IU/day of vitamin D3, 1 gram/day of omega-3 fatty acids, both, or placebo for a median of 5.3 years. Results were published in The New England Journal of Medicine in 2019.

The primary endpoint for the vitamin D arm was major adverse cardiovascular events (MACE): the composite of heart attack, stroke, and cardiovascular death. Vitamin D3 supplementation did not significantly reduce MACE compared with placebo (hazard ratio 0.97, 95% CI 0.85-1.12). On its face, this looks like a null result. However, secondary analyses told a more nuanced story.

What the Secondary Analyses Found

A pre-specified secondary analysis published separately in JAMA Cardiology found that vitamin D3 significantly reduced the risk of heart failure hospitalization (HR 0.73, 95% CI 0.54-0.98) and a composite of heart failure plus atrial fibrillation (HR 0.81, 95% CI 0.66-0.99). Myocardial infarction alone also showed a non-significant trend toward reduction.

Perhaps more telling: participants who were Black had a statistically significant reduction in total cardiovascular events (HR 0.77, 95% CI 0.63-0.95), a subgroup that often carries higher rates of vitamin D deficiency. This pattern is consistent with the hypothesis that repletion matters more when baseline status is genuinely low.

Other Key Trials: D-HEALTH, ViDA, and RECORD

VITAL is not the only large trial. The D-HEALTH trial, published in BMJ in 2020, randomized 311 older Australians to 60,000 IU/month of vitamin D3 (roughly 2,000 IU/day equivalent) versus placebo over three years. Blood pressure, a primary surrogate outcome for cardiovascular risk, was not significantly reduced. The trial was underpowered for hard cardiac endpoints, but it contributed to a broader picture of modest effects on vascular function at best.

The ViDA trial in New Zealand enrolled 5,110 adults and used 100,000 IU monthly. A report in JAMA found no significant effect on the composite of cardiovascular events, cancer, or other primary outcomes. However, ViDA was not specifically powered for cardiovascular endpoints alone, and baseline vitamin D status of participants was generally adequate (mean 25(OH)D around 26 ng/mL), raising the question of whether supplementing people who are not deficient will produce a cardiovascular benefit.

Earlier work, such as the RECORD trial published in The Lancet, primarily examined fractures, but subsequent analyses found no meaningful cardiovascular signal from 800 IU/day D3 plus calcium in elderly individuals. The dose may have been too low and the population too narrow to see an effect.

Blood Pressure and Arterial Stiffness: A Closer Look

Hypertension is one of the clearest mechanistic links between vitamin D and cardiovascular disease. The RAAS pathway is suppressed by adequate vitamin D, which in theory should lower blood pressure. A large individual participant data meta-analysis of 27 RCTs published in The Cochrane Database of Systematic Reviews found a small but statistically significant reduction in systolic blood pressure (about 2 mmHg) in trials where participants started with the lowest 25(OH)D levels. In people who were already sufficient, no meaningful effect was found.

Arterial stiffness is another mechanistic target. Pulse wave velocity, a validated marker of arterial stiffness and cardiovascular risk, has been inversely correlated with 25(OH)D in observational studies. RCT evidence on this specific endpoint is thinner and less consistent, though some smaller trials report modest improvements with supplementation in deficient individuals.

The Threshold Question: Does Baseline Status Change Everything?

Reading across the trial data, a consistent theme emerges: vitamin D supplementation in people who are already sufficient (30 ng/mL or above) does not appear to produce additional cardiovascular benefit. The benefit signal, when it does appear, concentrates in people who were genuinely deficient at baseline (below 20 ng/mL) or in groups with chronically low exposure.

A 2022 Mendelian randomization analysis in European Heart Journal used genetic proxies for lifelong lower vitamin D to test causality without confounding. The analysis found that genetically predicted lower 25(OH)D was causally associated with higher risk of ischemic heart disease and myocardial infarction, but primarily in people with very low predicted levels. Above roughly 20 ng/mL (50 nmol/L), the relationship flattened substantially. This is consistent with a threshold effect rather than a dose-response curve across the full range of population levels.

This threshold framing matters for how you interpret your own status. If you are consistently below 20 ng/mL, there is a reasonable, biologically plausible, and now partially trial-supported case for correcting that deficiency with sun exposure, supplements, or both. If you are already at 40 ng/mL (100 nmol/L), adding more is unlikely to confer additional cardiovascular protection based on current evidence.

Vitamin K2 and Calcium Distribution: A Related Pathway

One issue that comes up in discussions of vitamin D and cardiovascular health is arterial calcification. Vitamin D increases intestinal calcium absorption, and some researchers have raised the concern that without adequate vitamin K2 (specifically MK-7), the extra calcium absorbed could be deposited in arteries rather than bones. This is a plausible mechanism, though RCT data on the combined D3 plus K2 effect on cardiovascular endpoints specifically are still limited. The concern is the basis for the common practical recommendation to take vitamin D3 with K2 when supplementing at moderate to high doses, particularly in older adults.

Sun Exposure, Not Just Supplements, May Matter

Almost all RCTs to date have tested oral supplements rather than sun exposure per se. Sun exposure raises 25(OH)D but also triggers other physiological changes, including the release of nitric oxide from skin, which independently lowers blood pressure. A study in Journal of Investigative Dermatology demonstrated that UVA irradiation of skin produced measurable blood pressure reductions in human subjects through a nitric oxide-dependent mechanism, an effect that oral vitamin D supplementation cannot replicate. This suggests that at least some of the cardiovascular benefit attributed to higher vitamin D levels in sun-exposed populations may come from pathways beyond 25(OH)D itself.

That does not mean supplements are valueless. It means the story of how sunlight protects the cardiovascular system is likely broader than a single biomarker. Meaningful UVB is generated when the UV index reaches 3 or above, typically during mid-morning through mid-afternoon at mid-latitudes. For a full breakdown of when and where that threshold is met across seasons, see our guide on UV index and vitamin D by location.

What This Means for Practical Decisions

First, know your 25(OH)D level. Without a baseline, you cannot know whether you are in the zone where cardiovascular benefit from correction is plausible. The standard test is 25-hydroxyvitamin D, tested at least twice a year (end of summer and end of winter) to capture seasonal swings. Our guide to vitamin D testing explains what to ask for and how to interpret the numbers.

Second, if you are deficient (below 20 ng/mL), correction is warranted on general health grounds, and the cardiovascular data adds biological plausibility that getting to sufficient levels matters beyond bone health. A typical repletion approach for adults is 2,000 to 4,000 IU/day of D3, ideally with K2 (MK-7), taken with your largest meal. High-dose supplementation should be monitored with blood testing, since levels above 100 ng/mL can cause toxicity over time.

Third, sun exposure remains a meaningful tool, particularly during seasons and hours when UVB is available. People with darker skin tones require roughly three to five times more sun exposure than lighter-skinned individuals to produce the same amount of vitamin D, a factor that partly explains higher deficiency rates and worse cardiovascular outcomes in some groups. For more on how melanin changes the equation, see UV index and vitamin D by skin type.

Finally, vitamin D is not a heart medication. The VITAL trial is the best evidence to date, and it did not show a broad reduction in MACE. Vitamin D correction in deficient people is one useful lever, not a substitute for blood pressure management, physical activity, diet, and not smoking.

Key Takeaways

Observational data consistently link low vitamin D to higher cardiovascular risk, with the strongest signal below 20 ng/mL. Large RCTs, including VITAL, do not show a broad reduction in major cardiovascular events from supplementation in generally healthy, mostly sufficient populations. Secondary and subgroup analyses from VITAL suggest possible benefit for heart failure hospitalization and in groups with lower baseline levels, including Black participants. A Mendelian randomization analysis supports a causal threshold effect: risk rises mainly when 25(OH)D falls below the deficiency threshold, not across the entire distribution. Skin-mediated nitric oxide release from UVA may explain part of the cardiovascular benefit of sun exposure independently of vitamin D synthesis. Getting to sufficient levels (30 ng/mL and above, ideally 40 ng/mL or above) is a reasonable target; chasing higher levels through heavy supplementation has no current RCT support for additional heart benefit. If you supplement, D3 with K2 at a fat-containing meal is the practical standard, with blood testing to confirm you are in the target range.

What to do next

If you are not sure whether you are making meaningful vitamin D from sun right now, estimate your personal sun window using the Rays calculator, which accounts for your location, skin type, and current UV index. For ongoing tracking without manual input, Rays automatically detects outdoor time and shows you whether you are building toward your daily vitamin D target, day by day across every season.